viral
infecti
diseas
caus
signific
morbid
mortal
human
lower
respiratori
infect
deadliest
communic
diseas
caus
million
death
global
moreov
acquir
immunodefici
syndrom
aid
caus
human
immunodefici
viru
hiv
infect
kill
million
peopl
million
peopl
infect
hiv
global
combat
viral
diseas
vaccin
antivir
drug
employ
result
global
effort
smallpox
caus
variola
viru
infect
erad
smallpox
vaccin
vaccinia
viru
howev
develop
effect
vaccin
difficult
time
consum
certain
virus
escap
host
immun
respons
therefor
continu
develop
antivir
drug
vaccin
requir
combat
viral
diseas
approxim
drug
approv
treat
human
infecti
diseas
caus
follow
nine
virus
hiv
human
cytomegaloviru
hepat
b
viru
hbv
hepat
c
viru
hcv
herp
simplex
viru
influenza
viru
respiratori
syncyti
viru
varicella
zoster
viru
human
papillomaviru
addit
mani
antivir
drug
evalu
clinic
trial
one
threat
viral
infect
emerg
reemerg
virus
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
zika
viru
effect
antivir
drug
vaccin
emerg
virus
current
avail
drugresist
virus
emerg
high
mutat
rate
viral
genom
exhibit
mani
virus
particularli
rna
virus
also
repres
threat
global
health
almost
current
approv
antivir
drug
produc
chemic
synthesi
natur
product
contribut
develop
antivir
drug
provid
insight
synthesi
chemic
compound
virus
must
util
host
cellular
machineri
propag
knowledg
interact
recent
advanc
natur
product
exhibit
great
structur
divers
complex
thu
viral
host
protein
involv
viral
propag
target
develop
antivir
drug
natur
product
review
summar
antivir
microbi
product
discov
institut
microbi
chemistri
imc
discuss
antivir
compound
influenza
viru
hbv
two
virus
threaten
global
human
health
antivir
drug
two
virus
develop
antivir
compound
isol
imc
summar
tabl
addit
provid
summari
natur
compound
broadspectrum
antivir
discuss
futur
potenti
use
microbi
product
antivir
natur
compound
antivir
activ
focus
review
summar
tabl
nucleo
ide
analog
major
class
approv
antivir
drug
exert
therapeut
effect
incorpor
viral
dna
rna
inhibit
viru
replic
date
use
versatil
platform
develop
narrow
broadspectrum
antivir
moreov
natur
product
provid
motiv
develop
new
nucleo
ide
two
arabinosyl
nucleosid
spongouridin
spongothymidin
isol
marin
spong
subsequ
contribut
synthesi
vidarabin
arabinosyladenin
use
treatment
herp
simplex
viru
infect
professor
umezawa
colleagu
identifi
nucleosid
analog
actinobacteria
exhibit
antivir
activ
current
sever
class
antihiv
drug
avail
hiv
treatment
combin
therapi
use
term
highli
activ
antiretrovir
therapi
target
multipl
step
viru
life
cycl
significantli
reduc
morbid
mortal
zidovudin
azidothymidin
first
approv
hiv
treatment
us
food
drug
administr
drug
initi
use
chemotherapeut
intervent
hiv
infect
unmet
medic
need
increas
efficaci
reduc
advers
effect
higher
barrier
drugresist
mutat
remain
prompt
continu
effort
develop
new
antihiv
drug
context
imc
isol
microbi
product
antihiv
activ
benanomicin
bellenamin
among
benanomicin
also
exhibit
antifung
activ
may
advantag
treatment
aid
patient
fungal
infect
addit
synthes
hiv
revers
transcriptas
inhibitor
meanwhil
research
group
found
sever
compound
discov
imc
exhibit
inhibitori
activ
virus
phleomycin
antipolioviru
activ
fusar
acid
broadspectrum
antivir
activ
herp
simplex
viru
varicellazost
viru
hbv
hcv
sindbi
viru
aclacinomycin
antiphag
activ
clazamycin
b
antiherp
simplex
viru
activ
sarkomycin
antirna
phage
activ
among
phleomycin
aclacinomycin
discov
antibiot
exhibit
antitumor
activ
presum
consequ
interact
cellular
current
microbi
secondari
metabolit
well
establish
contain
mani
compound
structur
chemic
divers
professor
umezawa
et
al
postul
certain
compound
among
may
target
enzym
reaction
start
search
enzym
inhibitor
microbi
ferment
broth
pioneer
work
contribut
variou
biochem
advanc
therapeut
approach
certain
diseas
exampl
field
viru
research
leupeptin
inhibitor
serin
cystein
proteas
streptomyc
shown
prevent
glycoproteinmedi
entri
marburg
viru
suggest
role
unknown
host
proteas
glycoprotein
antipain
elastatin
inhibitor
serin
cystein
proteas
use
inhibit
polioviru
notabl
pepstatin
aspart
proteinas
inhibitor
isol
sever
speci
made
signific
contribut
develop
key
class
antihiv
drug
highli
activ
antiretrovir
therapi
hiv
proteinas
process
viral
polyprotein
gener
matur
protein
essenti
viru
life
cycl
acetylderiv
pepstatin
report
highli
effect
hiv
proteas
transit
state
mimic
led
ration
design
peptidebas
proteas
furthermor
siastatin
b
analog
sialic
acid
isol
streptomyc
verticillu
var
quantum
sialidas
although
siastatin
b
show
effect
sialidas
activ
influenza
viru
neuraminidas
na
epimer
analog
significantli
inhibit
enzymat
activ
viru
propag
vitro
describ
togeth
imc
identifi
mani
microbi
product
antivir
activ
play
promin
role
uniqu
pharmacophor
antivir
drug
season
influenza
acut
respiratori
infect
caus
influenza
virus
three
type
season
influenza
b
c
influenza
b
virus
caus
outbreak
epidem
world
health
organ
estim
annual
epidem
caus
influenza
b
virus
result
million
case
sever
ill
death
furthermor
influenza
pandem
spanish
influenza
asian
influenza
hong
kong
influenza
russian
influenza
influenza
swineorigin
occur
new
influenza
viru
human
popul
immun
emerg
consequ
genet
reassort
epidem
pandem
still
occur
continu
discoveri
develop
new
antivir
drug
vaccin
influenza
infect
requir
total
eight
drug
matrix
inhibitor
amantadin
rimantadin
na
inhibitor
zanamivir
oseltamivir
peramivir
laninamivir
octano
viral
rnadepend
rna
polymeras
inhibitor
ribavirin
favipiravir
approv
treatment
influenza
infect
amantadin
first
synthet
compound
shown
inhibit
influenza
viru
approv
treat
influenza
viru
infect
target
amantadin
integr
membran
protein
exhibit
h
ion
channel
activ
acidif
viruscontain
endosom
activ
ion
channel
acidif
virion
interior
necessari
allow
viral
genom
diffus
away
endosom
membran
amantadin
inhibit
proton
transloc
bind
transmembran
domain
protein
tetram
therebi
induc
releas
viral
genom
figur
howev
amantadin
rimantadin
deriv
amantadin
current
use
treat
influenza
viru
infect
drugresist
virus
emerg
rapidli
season
epidem
strain
amantadineresist
mutat
central
nervou
system
side
effect
particularli
common
patient
treat
amantadin
hemagglutinin
ha
na
two
major
glycoprotein
express
influenza
b
virus
ha
mediat
bind
virus
target
cell
via
termin
sialic
acid
na
cleav
termin
sialic
acid
host
cell
na
activ
facilit
releas
progeni
influenza
viru
digest
sialic
acid
ha
receptor
figur
sialidas
activ
na
target
develop
antiinfluenza
drug
siastatin
b
analog
sialic
acid
inhibit
sialidas
activ
clostridium
perfrigen
na
inhibit
influenza
viru
strain
na
newcastl
diseas
viru
sato
strain
siastatin
b
epimer
analog
b
inhibit
sialidas
activ
influenza
b
virus
na
propag
influenza
synthet
analog
neuramin
acid
acid
found
inhibitor
influenza
viru
consid
transit
state
analog
bind
activ
site
base
structur
analysi
complex
analog
synthes
specif
influenza
viru
na
activ
analog
test
among
analog
zanamivir
exhibit
antivir
activ
variou
influenza
b
guanidin
group
zanamivir
suggest
form
salt
bridg
na
activ
site
strong
interact
na
poor
oral
bioavail
zanamivir
administ
inhal
improv
oral
bioavail
novel
analog
synthes
base
xray
crystallograph
analysi
na
key
one
analog
inhibit
influenza
viru
na
activ
na
inhibit
activ
compar
zanamivir
oseltamivir
ethylest
prodrug
oral
bioavail
oseltamivir
improv
compar
zanamivir
oseltamivir
two
na
inhibitor
peramivir
laninamivir
octano
peramivir
administ
intraven
administr
laninamivir
octano
administ
inhal
two
drug
use
singledos
treatment
influenza
b
virus
viral
polymeras
complex
promis
target
develop
antiinfluenza
drug
transcript
replic
critic
step
viru
propag
moreov
viral
polymeras
complex
act
specif
molecular
mechan
viral
transcript
replic
viral
polymeras
complex
heterotrim
compos
three
subunit
pa
initi
viral
mrna
transcript
influenza
viral
polymeras
synthes
structur
mrna
necessari
translat
use
uniqu
capsnatch
mechan
steal
cap
structur
mrna
host
hostcel
premrna
bound
subunit
via
structur
cleav
nucleotid
endonucleas
activ
pa
subunit
use
cap
fragment
primer
viral
polymeras
complex
synthes
viral
mrna
process
target
develop
antiinfluenza
drug
two
inhibitor
pimodivir
phase
clinic
trial
respect
inhibitor
bind
capbind
pocket
molecul
identifi
lead
compound
antiinfluenza
viru
activ
phenotyp
screen
target
compound
determin
subunit
base
structur
inform
complex
synthes
repres
oral
bioavail
compound
effect
influenza
viru
influenza
b
viru
specif
inhibit
endonucleas
activ
pa
thu
prevent
cleavag
host
premrna
effect
influenza
influenza
b
viru
infect
two
approv
drug
ribavirin
favipiravir
inhibit
influenza
viral
rna
synthesi
figur
ribavirin
synthet
nucleosid
analog
metabol
triphosph
form
ribavirintp
ribavirintp
inhibit
rna
polymeras
complex
influenza
viru
compet
atp
ribavirin
use
treat
influenza
viru
infect
use
hcv
infect
along
pegyl
interferon
pyrazin
deriv
metabol
act
specif
inhibitor
influenza
viru
rna
synthesi
directli
inhibit
viral
rna
synthesi
incorpor
synthes
rna
monophosph
form
without
chain
incorpor
induc
misincorpor
incorrect
nucleotid
larg
fraction
progeni
virion
cell
exhibit
infect
approv
use
pandem
influenza
infect
japan
approv
clinic
trial
drug
mention
synthes
natur
product
antiinfluenza
viru
drug
screen
studi
na
target
antiinfluenza
viru
activ
natur
product
highthroughput
assay
system
measur
na
activ
construct
report
natur
product
show
inhibit
na
classifi
five
group
flavonoid
oligostiben
coumarin
diarylheptanoid
ha
also
target
screen
antiinfluenza
viru
drug
novel
compound
pentacycl
structur
stachyflin
isol
stachybotri
inhibit
conform
chang
ha
low
ph
therebi
inhibit
membran
fusion
viru
host
hbv
small
envelop
hepatotrop
dna
viru
kb
partial
doublestrand
relax
circular
dna
genom
encod
polymeras
precor
hbv
e
antigen
core
capsid
surfac
antigen
small
middl
larg
hbx
protein
transcript
activ
shown
figur
viru
enter
hepatocyt
bind
cellular
receptor
includ
sodium
taurochol
cotransport
follow
releas
nucleocapsid
relax
circular
dna
transport
nucleu
convert
coval
close
circular
dna
cccdna
cccdna
quit
stabl
form
minichromosom
serv
templat
transcript
viral
mrna
among
mrna
kb
pregenom
rna
translat
polymeras
core
protein
encapsid
togeth
polymeras
serv
rna
replic
intermedi
pregenom
rna
revers
transcrib
minusstrand
dna
degrad
rnase
h
activ
associ
polymeras
process
hbv
polymeras
subsequ
synthes
plusstrand
dna
variou
length
gener
relax
circular
dna
final
matur
nucleocapsid
releas
infect
cell
acquisit
envelop
contain
surfac
antigen
endoplasm
reticulum
golgi
apparatu
produc
progeni
virion
recycl
nucleu
suppli
cccdna
pool
identifi
promis
lead
compound
drug
develop
import
select
potenti
therapeut
target
chronic
hbv
infect
viru
life
cycl
although
variou
antihbv
drug
beyond
scope
review
subject
preclin
clinic
inhibitori
mechan
provid
help
data
make
reason
select
key
target
drug
screen
microbi
product
approv
nucleo
ide
analog
competit
inhibit
dna
elong
viral
polymeras
convers
triphosph
form
cellular
enzym
although
nucleo
ide
analog
inhibitor
highli
effect
prevent
liver
diseas
progress
drug
cur
requir
longterm
use
associ
risk
drugresist
sideeffect
overcom
drawback
sever
nucleo
ide
analog
current
preclin
clinic
trial
indic
activ
site
dna
polymer
remain
indispens
drug
target
hbv
treatment
inde
new
tenofovir
deriv
tenofovir
alafenamid
vemlidi
recent
approv
improv
pharmacolog
properti
contribut
reduct
nephrotox
date
microbi
metabolit
yield
variou
nucleo
ide
analog
mention
includ
oxetanocin
deriv
exhibit
antihbv
ideal
goal
antihbv
treatment
loss
viral
surfac
antigen
hbsag
correl
dramat
reduct
incid
hepatocellular
carcinoma
howev
current
nucleo
ide
inhibitor
ineffect
regard
littl
effect
cccdna
pool
serv
templat
hbsag
express
improv
treatment
outcom
novel
antihbv
agent
target
step
viral
dna
synthesi
combin
current
hbv
drug
may
promot
cccdna
decay
provid
higher
barrier
core
protein
selfassembl
form
nucleocapsid
viral
dna
synthesi
carri
sever
inhibitor
process
phase
iii
clinic
trial
furthermor
inhibitor
may
facilit
cccdna
decay
strong
inhibit
viral
dna
synthesi
thought
complet
block
recycl
nucleocapsid
nucleu
cccdna
thu
perturb
capsid
assembl
process
would
promis
approach
novel
hbv
treatment
deriv
leucamid
cyclic
heptapeptid
deriv
spong
found
interfer
furthermor
rnase
hmediat
pregenom
rna
degrad
anoth
essenti
step
viral
dna
synthesi
novel
inhibitor
activ
undergo
preclin
nucleolyt
cleavag
depend
metal
ion
coordin
activ
site
rnase
h
class
metalchel
inhibitor
might
potenti
develop
novel
rnase
h
inhibitor
although
show
inhibitori
activ
toward
hbv
rnase
h
plant
hydroxyl
tropolon
often
found
microbi
taken
togeth
appear
like
microbi
metabolit
repres
enthral
resourc
new
chemic
entiti
target
hbv
dna
synthesi
gener
natur
product
screen
timeconsum
process
requir
fraction
isol
activ
compound
complex
extract
unknown
composit
recent
develop
system
facilit
detect
replic
hbv
genom
use
adenoviru
use
quantit
evalu
inhibitori
potenc
test
compound
shorter
period
time
model
system
studi
hbv
replic
use
cell
line
similarli
new
effici
detect
method
viru
replic
would
allow
rapid
drug
screen
natur
resourc
hbv
infect
significantli
influenc
variou
host
factor
host
factortarget
antivir
prospect
therapeut
myrcludexb
peptid
mimic
nterminu
larg
surfac
antigen
involv
bind
sodium
taurochol
cotransport
polypeptid
block
viru
entri
hepatocyt
current
phase
ii
clinic
recent
cyclosporin
fungal
cyclic
polypeptid
analog
report
inhibit
viru
entri
target
sodium
taurochol
cotransport
macrocycl
peptid
scaffold
often
advantag
occupi
interfac
requir
interact
receptor
bind
capsid
assembl
describ
moreov
host
enzym
essenti
viru
replic
repres
promis
drug
target
deoxynojirimycin
iminosugar
inhibitor
analog
shown
reduc
hbv
secret
infect
iminosugar
potenti
develop
antivir
drug
disrupt
fold
viral
glycoprotein
inhibit
host
glucosidas
local
endoplasm
deoxynojirimycin
plant
origin
class
compound
also
found
microbi
metabolit
siastatin
b
describ
although
effect
siastatin
b
hbv
replic
present
unknown
host
glucosidas
involv
antigen
virion
secret
might
suitabl
target
antihbv
drug
screen
microbi
metabolit
furthermor
sever
therapeut
vaccin
treatment
chronic
hbv
infect
preclin
clinic
trial
approach
aim
stimul
either
specif
nonspecif
immun
respons
hbv
elimin
cccdna
pool
adjuv
may
work
enhanc
vaccin
previous
bestatin
ubenimex
immunomodul
discov
report
enhanc
immun
respons
hiv
vaccin
murin
although
effect
hbv
vaccin
unknown
compound
adjuv
activ
hbv
vaccin
might
present
microbi
metabolit
recent
deadli
diseas
outbreak
caus
emerg
reemerg
virus
becom
increasingli
threaten
includ
outbreak
nipah
viru
malaysia
hendra
viru
australia
hantaviru
unit
state
ebola
viru
africa
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
coronavirus
china
mideast
zika
viru
oceania
america
influenza
viru
subtyp
effici
vaccin
specif
antivir
drug
emerg
reemerg
viru
diseas
yet
avail
antivir
drug
specif
viru
infect
also
broadspectrum
antivir
drug
need
develop
summar
candid
broadspectrum
antivir
drug
nucleosid
analog
drug
host
protein
discuss
potenti
natur
compound
broadspectrum
antivir
drug
nucleosid
analog
candid
use
broadspectrum
antivir
drug
ribavirin
known
broadspectrum
rna
viru
inhibitor
antivir
candid
emerg
infecti
diseas
dengu
viru
noroviru
hendra
nipah
potenti
activ
ribavirin
broadspectrum
rna
virus
exert
direct
indirect
inhibit
viral
polymeras
activ
ribavirin
monophosph
inhibit
dehydrogenas
catalyz
reaction
xanthosin
monophosph
therebi
decreas
intracellular
gtp
nucleotid
pool
imbal
result
ribavirin
treatment
could
caus
reduct
viral
polymeras
activ
incorpor
altern
nucleotid
gtp
recent
report
suggest
also
broadspectrum
rna
viru
inhibitor
virus
ebola
detail
mechan
antivir
activ
rna
virus
known
merit
studi
nucleosid
analog
subject
clinic
trial
ebola
viru
also
exhibit
broadspectrum
antivir
effect
rna
viru
famili
includ
filovirus
arenavirus
paramyxovirus
mention
natur
product
contribut
develop
antivir
nucleotid
analog
new
class
nucleotid
analog
deriv
natur
product
promis
lead
compound
emerg
virus
drug
nonvir
protein
host
protein
also
broadspectrum
antivir
drug
candid
virus
use
common
cellular
machineri
entri
exit
host
cell
inhibitor
cellular
machineri
could
inhibit
viral
propag
host
target
drug
yet
approv
antivir
research
develop
ongo
rna
virus
known
use
host
membran
compart
replic
traffick
thu
lipid
metabol
candid
target
antivir
drug
statin
first
isol
penicillium
citrinum
hydroxymethylglutarylcoenzym
reductas
inhibitor
treatment
statin
decreas
level
lowdens
lipoprotein
antivir
effect
stain
report
hbv
hiv
influenza
viru
dengu
viru
human
cytomegaloviru
antivir
activ
statin
may
consequ
disrupt
membran
compon
virus
use
along
chang
membran
traffick
serin
palmitoyltransferas
inhibitor
myriocin
isol
myriococcum
isol
fusarium
also
inhibit
propag
hcv
hbv
influenza
serin
palmitoyltransferas
act
sphingomyelin
synthesi
pathway
sphingomyelin
essenti
compon
lipid
raft
myriocin
inhibit
intracellular
transport
influenza
viru
glycoprotein
disrupt
hcv
replic
complex
drug
reposit
also
known
drug
repurpos
grow
interest
reduc
time
cost
associ
drug
develop
cyclosporin
csa
approv
immunosuppress
drug
reveal
csa
effect
virus
hiv
human
papillomaviru
influenza
viru
hcv
coronavirus
human
csa
isol
hypocladium
inflatum
gam
inhibit
prolyl
isomeras
cyclophilin
implic
regul
protein
antivir
mechan
csa
involv
inhibit
correct
fold
viral
protein
cyclophilin
csa
exert
immunosuppress
effect
complex
form
inhibit
calciumdepend
phosphatas
activ
calcineurin
lead
inhibit
key
activ
cell
therefor
csa
deriv
lack
inhibitori
activ
calcineurin
maintain
inhibitori
activ
cyclophilin
csa
deriv
alisporivir
ribavirin
studi
antihcv
drug
subject
clinic
today
viral
protein
major
target
antivir
drug
antivir
drug
specif
target
protein
success
import
infecti
diseas
hiv
hcv
rapidli
increas
knowledg
protein
structur
develop
silico
tool
method
chemic
genet
modif
antivir
drug
develop
contribut
futur
elimin
specif
infecti
diseas
concurr
face
threat
emerg
reemerg
infecti
diseas
avail
specif
antivir
drug
prevent
pandem
infect
broadspectrum
antivir
drug
also
need
develop
natur
product
rich
sourc
promis
start
point
identifi
lead
compound
antivir
target
host
protein
studi
virushost
interact
omic
data
viru
infect
cell
help
us
acceler
develop
screen
system
identif
potenti
drug
target
anticip
novel
antivir
drug
deriv
microbi
product
contribut
elimin
specif
viru
infect
emerg
viru
infect
futur
dedic
review
prof
hamao
umezawa
